Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform

Drug firm Lupin Ltd on Thursday (October 9) announced the launch of a strategic partnership program to expand the reach of its long-acting injectable (LAI) platform, PrecisionSphere, developed by its subsidiary Nanomi B.V.

PrecisionSphere has demonstrated efficacy and safety in drug delivery and is now ready for commercial use, following the recent approval from the United States Food and Drug Administration (U.S. FDA) for the first product developed using the platform.

Through the new partnership program, Lupin aims to collaborate with companies seeking to extend their product lifecycles, including those with products in development or already on the market. The initiative is particularly focused on enabling partners to benefit from longer-acting formulations, thereby enhancing patient compliance and treatment outcomes.

Also Read: Lupin shares surge over 3% on $250 million investment plans for new US facility

Dr Fabrice Egros, President – Corporate Development, Lupin, said, "With the validation of PrecisionSphere's capabilities and our proven track record of executing several key strategic partnerships each year, we are ready to expand patient access to advanced LAI treatments through new global strategic collaborations."

PrecisionSphere addresses key compliance issues that lead pharmaceutical companies to lose millions in revenue and experience failed treatment results.

Unlike conventional LAI technologies that produce variable particle sizes, this platform allows pharmaceutical companies to manufacture medicines with consistent particle size, shape, and biological properties, leading to improved injectability. It also enables optimised drug levels—the release of consistent drug concentrations throughout the treatment, ranging from weeks to months.

Dr Shahin Fesharaki, Chief Scientific Officer, Lupin, said, “PrecisionSphere reflects our commitment to innovation and leverages our regulatory expertise, scalable manufacturing capabilities, and flexible collaboration models to lower entry barriers for developing LAIs. This allows partners to efficiently bring advanced LAIs to market across various therapeutic areas and potentially extend the patent life of their products."

Also Read: Lupin launches blood sugar control injection in US

For patients, reduced injection frequency enhances convenience and may lead to greater compliance and potentially better treatment outcomes. For healthcare professionals, this technology would make it possible to control the delivery of a drug at the optimal therapeutic dose during treatment.

Shares of Lupin Ltd ended at ₹1,956.10, up by ₹50.50, or 2.65%, on the BSE.Read about our editorial guidelines and ethics policy